Clinical trials: Dry Macular Degeneration
Dry Age-related Macular Degeneration
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.
- Trial name
- NCT04065490
- Testing
- Valeda Light Delivery System
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- LumiThera, Inc.
Geographic Atrophy
Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy
This is AGX-08's safety, tolerability, and efficacy in Geographic Atrophy first-in-human study. This trial is meant to evaluate the safety and efficacy of AGX-08 in Geographic Atrophy patients.
- Trial name
- NCT07602127
- Testing
- AGX-08-L, AGX-08-H, AGX-08-S
- Volunteers
- 24 people
- Sponsor
- Augelux Therapeutics
Wet Age-related Macular Degeneration
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
GALATIR is a double blind randomized clinical trial comparing efficacy and safety of BCD-021 (bevacizumab) and Lucentis® (ranibizumab) in patients with neovascular wet age-related macular degeneration.
- Trial name
- GALATIR (NCT02036723)
- Testing
- Bevacizumab, Ranibizumab
- Where
- 13 sites in Brazil, Russia
- Sponsor
- Biocad
Age-Related Macular Degeneration
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy…
- Trial name
- NCT05230537
- Testing
- Iptacopan (LNP023)
- Where
- 28 sites in United States, China and 2 more
- Volunteers
- 168 people
- Sponsor
- Novartis Pharmaceuticals
Dry Age-related Macular Degeneration
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)
The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with…
- Trial name
- NCT06351605
- Testing
- Valeda® Light Delivery System
- Where
- 6 sites in United States, Norway
- Volunteers
- 500 people
- Sponsor
- LumiThera, Inc.
Geographic Atrophy, Dry Age-Related Macular Degeneration
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration…
- Trial name
- NCT02686658
- Testing
- Avacincaptad Pegol
- Where
- 78 sites in United States, Croatia and 5 more
- Volunteers
- 286 people
- Sponsor
- IVERIC bio, Inc.
Geographic Atrophy
Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following single and multiple intravitreal (ITV) administrations in patients with GA secondary to AMD.
- Trial name
- NCT03295877
- Testing
- RO7171009
- Where
- 13 sites in United States
- Volunteers
- 28 people
- Sponsor
- Genentech, Inc.
Geographic Atrophy
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) secondary to Age-related Macular…
- Trial name
- NCT07215234
- Testing
- SAR446597
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 104 people
- Sponsor
- Sanofi
Dry Age-related Macular Degeneration
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
To evaluate the safety and exploratory efficacy of 1.0mg of Luminate® in patients with Intermediate Non-Exudative Macular Degeneration
- Trial name
- NCT03626636
- Testing
- Risuteganib
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Allegro Ophthalmics, LLC
Neovascular Age-related Macular Degeneration
Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
AMD (Age Related Macular Degeneration) is the leading cause of severe visual loss and blindness registration in the UK . It is a disease which affects the retina (the nerve and blood vessel network at the back of the eye…
- Trial name
- SAFARI (NCT02161575)
- Testing
- Ranibizumab
- Where
- 28 sites in Germany, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Geographic Atrophy, Macular Degeneration
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
- Trial name
- NCT06635148
- Testing
- JNJ-81201887
- Where
- 104 sites in United States, Australia and 16 more
- Volunteers
- 274 people
- Sponsor
- Janssen Research & Development, LLC
Geographic Atrophy
A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study was to to demonstrate superiority of AL-78898A intravitreal (IVT) injections compared to sham injections by assessing mean geographic atrophy (GA) lesion size change from baseline at Month 12.
- Trial name
- NCT01603043
- Testing
- Al-78898A
- Volunteers
- 10 people
- Sponsor
- Alcon Research
Atrophy, Geographic
Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers
This study is intended to enable a possible transition to intramuscular (IM) or subcutaneous (SQ) administration for subsequent studies with GSK933776 by characterizing the safety, tolerability, PK and pharmacodynamic profiles…
- Trial name
- NCT02033668
- Testing
- GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Geographic Atrophy
A Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD).
- Trial name
- Proxima A (NCT02479386)
- Testing
- No intervention
- Where
- 91 sites in United States, Argentina and 13 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Geographic Atrophy
A Study of NGM621 in Participants With Geographic Atrophy
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
- Trial name
- CATALINA (NCT04465955)
- Testing
- NGM621
- Where
- 65 sites in United States
- Volunteers
- 320 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Advanced Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
This study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration.
- Trial name
- NCT01255462
- Testing
- LFG316
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Dry Age-Related Macular Degeneration
A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injection in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD).
- Trial name
- NCT00950638
- Testing
- Avacincaptad Pegol
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Ophthotech Corporation
Geographic Atrophy
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
- Trial name
- NCT03525600
- Testing
- APL-2
- Where
- 141 sites in United States, Argentina and 13 more
- Volunteers
- 621 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)
Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD
This is a parallel, randomized, open-label, controlled study to evaluate the efficacy and safety of oral EG-301 in patients with intermediate non-exudative (dry) age-related macular degeneration (dAMD).
- Trial name
- NCT05170048
- Testing
- EG-301, AREDS2 supplements
- Volunteers
- 90 people
- Sponsor
- Evergreen Therapeutics, Inc.